Never mind the QALY, feel the budget impact for orphan drugs say UK industry
This article was originally published in Scrip
EMIG, an association representing 135 small to medium sized pharmaceutical and biopharmaceutical firms in the UK, has warned that the country's new value based pricing system should not use the QALY (quality adjusted life year) to determine the value of treatments for rare diseases. Instead, EMIG argues that the low overall budgetary impact of rare diseases ought to be taken into account, as well as the absence of alternative therapeutic options.
You may also be interested in...
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.